Company news
Arovella Therapeutics Limited (ASX:ALA) news
Arovella Therapeutics Limited news releases on 6ix. Latest, Aug 31, 2022: Preliminary Final Report
Press releases — page 2
Preliminary Final Report
August 31, 2022
Arovella Therapeutics : Quarterly Appendix 4C and Activities Report
July 28, 2022
Sumatriptan Update
June 27, 2022
ZolpiMist Launch Australia
June 22, 2022
Arovella Therapeutics : Adopts WEF Framework For ESG Reporting
June 7, 2022
Services Agreement with Q-Gen for CAR19-iNKT manufacture
April 20, 2022
Anagrelide patent for the United States
April 5, 2022
Arovella Therapeutics : Proposed issue of securities - ALA
March 17, 2022
Arovella Therapeutics : Application for quotation of securities - ALA
March 16, 2022
Arovella Therapeutics : Update - Proposed issue of securities - ALA
February 28, 2022
Arovella SPP Closed early over subscribed
February 21, 2022
Investor Presentation
January 31, 2022
SPP Offer Booklet
January 23, 2022
Arovella Completes $4.57M Placement & Launches $1.5M SPP
January 23, 2022
AGM FY21 Presentation
December 15, 2021
Arovella licences novel monoclonal antibody from MD Anderson
December 12, 2021
Chile Ministry of Health Approval Granted for ZolpiMist
October 20, 2021
GM presentation
October 13, 2021
Dr Reuben Benjamin Appointed to SUDA iNKT Cell Therapy SAB
August 25, 2021
SUDA signs Licence and Distribution Agreement with STADA
August 24, 2021
ZolpiMist Update
August 23, 2021
iNKT cell therapy platform update
August 16, 2021
SUDA appoints new cell and gene therapy manufacturing expert
August 1, 2021
Disclosure Document Prospectus $3.65m
June 22, 2021
SUDA Placement Raises $3.65m
June 22, 2021
Investor Presentation incorporating iNKT Cell Platform
June 18, 2021
SUDA Licenses a Novel iNKT Cell Therapy Platform
June 18, 2021
Investor Presentation March 2021
March 29, 2021
Anagrelide Project Update
February 25, 2021
Zelira Therapeutics Feasibility Study Update
February 15, 2021
Company Update - Letter to Shareholders
December 21, 2020
Prospectus - Placement
December 15, 2020
AGM FY20 Chairmans address and virtual meeting guide
November 25, 2020
R & D Tax Incentive refund received
November 23, 2020
Investor Presentation November 2020
November 16, 2020
Anagrelide Cancer Patent For Australia
September 8, 2020
Appendix 4C - quarterly
July 31, 2020
TGA Approval Granted For ZolpiMist
July 28, 2020
Prospectus For Entitlement Offer
July 2, 2020
Market Update
June 24, 2020
Suspension from Official Quotation
June 4, 2020
Anagrelide Cancer Patent For Japan
May 20, 2020
SUDA Signs Additional Licence With Mitsubishi Tanabe
March 22, 2020
Half Yearly Report and Accounts
February 26, 2020
SANOFI and SUDA Entered Into A Feasibility Agreement
December 8, 2019
SUDA Signs Co-Development Deal With Ordesa
December 4, 2019
SUDA Appoints Dr Michael Baker CEO
November 26, 2019
Case For Share Consolidation and Appendix 3A.3
November 3, 2019
SUDA Finalises Agreement With Cann Pharmaceutical
October 29, 2019
Response to ASX Query regarding Accounts
October 2, 2019